Argos Therapeutics, Inc. and Therakos, Inc. Enter Exclusive Agreement for Regulatory T Cell Technology
11/16/2007 9:55:42 AM
DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics announced today that it has granted Therakos, Inc., a Johnson & Johnson company, an exclusive license for the research and development of novel treatments based on regulatory T cell technology developed by Argos. Terms of the agreement were not disclosed.